Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Bicalutamide may effectively treat female pattern hair loss with minimal side effects.

A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

A woman's adrenal tumor disappeared after treatment with cyproterone acetate.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Bicalutamide improves hair density in women safely.

Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.

Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.

Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.

Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.

Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.

New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.

Flutamide, a medication used for excessive hair growth, can cause severe liver damage in women.

Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.